Citius Pharmaceuticals Inc (CTXR)

$0.80 -0.24 (-23.02%)
Market Cap 17.69M
Revenue (ttm) 0.00
Net Income (ttm) -39.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 18,729,000
Avg Vol 1,339,696
Day's Range N/A - N/A
Shares Out 17.01M
Stochastic %K 30%
Beta 1.51
Analysts Sell
Price Target $6.00

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 967 6677
Address:
11 Commerce Drive, First Floor, Cranford, United States
Goldwave9
Goldwave9 Dec. 25 at 12:25 AM
$CTXR I love the position on the chart if you're a bottom fisher. It also hit my scanner, which is seldom wrong--If you give it some time here. (And yes, I know it looked real crappy today.)
0 · Reply
Applebat
Applebat Dec. 24 at 11:39 PM
$CTXR 2 or 3 weeks later and here we are. so bulls... same question.
0 · Reply
SweStonk
SweStonk Dec. 24 at 8:22 PM
$CTXR you mean I said? 😘
1 · Reply
OkIGuess
OkIGuess Dec. 24 at 8:21 PM
$CTXR Stocks go up. Stocks go down. Will wait and see here. They got until March to figure something out. If they have something viable, somebody will absorb
0 · Reply
Gabriel5498
Gabriel5498 Dec. 24 at 7:09 PM
$CTXR
1 · Reply
Alder77
Alder77 Dec. 24 at 6:27 PM
$CTXR Excellent scalping day in the 0.63-0.85 channel. Double trade. I preferred to exit late in the game. It's easy to buy back in the game at lower levels. In my opinion, the trend remains negative, but as long as volumes remain, there are excellent scalping opportunities.
0 · Reply
yamihere2
yamihere2 Dec. 24 at 5:54 PM
$CTXR Got scammed so bad here in 2021. Criminal, and it’s all legal?? Throw the old fk in jail
1 · Reply
Cholo_Swing_Trades
Cholo_Swing_Trades Dec. 24 at 5:43 PM
$CTXR wow hit .60s again after i sold this 2 years ago i made all my money back trading real stocks
0 · Reply
900fix
900fix Dec. 24 at 5:31 PM
$CTXR ML was slow walked. That was the start. It was all a scam by Lenny. He should be in jail with the board and that dim wit so called analyst Jason who kept pumping this.
0 · Reply
Justrise07
Justrise07 Dec. 24 at 4:51 PM
$MGRX 2pt $CTXR cover your loss
0 · Reply
Latest News on CTXR
Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus

Dec 24, 2025, 5:32 AM EST - 19 hours ago

Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus

ASTS METC MWG PATH

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025, 4:30 PM EST - 1 day ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025, 4:30 PM EST - 1 day ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 10, 2025, 4:30 PM EST - 14 days ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2025, 8:30 AM EST - 15 days ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Dec 4, 2025, 8:37 AM EST - 20 days ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTOR

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Dec 1, 2025, 12:00 PM EST - 23 days ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTOR

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2025, 8:00 AM EST - 4 weeks ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTOR

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Nov 21, 2025, 8:37 AM EST - 4 weeks ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTOR

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025, 4:30 PM EDT - 2 months ago

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Oct 21, 2025, 8:16 AM EDT - 2 months ago

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

NEUP PCAR

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025, 8:00 AM EDT - 2 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Oct 17, 2025, 5:00 PM EDT - 2 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTOR

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Oct 16, 2025, 8:47 AM EDT - 2 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTOR

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 10, 2025, 4:30 PM EDT - 3 months ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 9, 2025, 8:30 AM EDT - 3 months ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

Aug 22, 2025, 8:47 AM EDT - 4 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTOR

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:30 PM EDT - 4 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Oncology Announces Closing of $9.0 Million Public Offering

Jul 17, 2025, 4:30 PM EDT - 5 months ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTOR

Citius Oncology Announces Pricing of $9.0 Million Public Offering

Jul 16, 2025, 9:15 AM EDT - 5 months ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTOR

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Jul 15, 2025, 8:32 AM EDT - 5 months ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTOR

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 8, 2025, 8:34 AM EDT - 6 months ago

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Jun 17, 2025, 8:08 AM EDT - 6 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTOR

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 12, 2025, 8:35 AM EDT - 6 months ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 10, 2025, 7:00 AM EDT - 7 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:30 PM EDT - 8 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 8:37 AM EDT - 8 months ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Apr 1, 2025, 9:00 AM EDT - 9 months ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 14, 2025, 4:30 PM EST - 11 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTOR

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Feb 6, 2025, 8:55 AM EST - 11 months ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTOR

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 8, 2025, 8:00 AM EST - 1 year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTOR

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 6, 2025, 7:50 AM EST - 1 year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTOR

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Dec 27, 2024, 5:00 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Nov 25, 2024, 8:03 AM EST - 1 year ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Nov 22, 2024, 9:00 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Nov 18, 2024, 4:05 PM EST - 1 year ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Nov 15, 2024, 1:30 PM EST - 1 year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Nov 11, 2024, 8:45 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 5:28 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

Aug 12, 2024, 4:22 PM EDT - 1 year ago

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Aug 8, 2024, 6:59 AM EDT - 1 year ago

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Jul 18, 2024, 7:00 AM EDT - 1 year ago

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Analysts Hunt for Undervalued Biotech Stocks

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Analysts Hunt for Undervalued Biotech Stocks

Bloodstream Infections - From Threats to Solutions

Jul 11, 2024, 11:00 AM EDT - 1 year ago

Bloodstream Infections - From Threats to Solutions

Biopharma Stocks Transformative Innovation for the Future of Health

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Biopharma Stocks Transformative Innovation for the Future of Health

Goldwave9
Goldwave9 Dec. 25 at 12:25 AM
$CTXR I love the position on the chart if you're a bottom fisher. It also hit my scanner, which is seldom wrong--If you give it some time here. (And yes, I know it looked real crappy today.)
0 · Reply
Applebat
Applebat Dec. 24 at 11:39 PM
$CTXR 2 or 3 weeks later and here we are. so bulls... same question.
0 · Reply
SweStonk
SweStonk Dec. 24 at 8:22 PM
$CTXR you mean I said? 😘
1 · Reply
OkIGuess
OkIGuess Dec. 24 at 8:21 PM
$CTXR Stocks go up. Stocks go down. Will wait and see here. They got until March to figure something out. If they have something viable, somebody will absorb
0 · Reply
Gabriel5498
Gabriel5498 Dec. 24 at 7:09 PM
$CTXR
1 · Reply
Alder77
Alder77 Dec. 24 at 6:27 PM
$CTXR Excellent scalping day in the 0.63-0.85 channel. Double trade. I preferred to exit late in the game. It's easy to buy back in the game at lower levels. In my opinion, the trend remains negative, but as long as volumes remain, there are excellent scalping opportunities.
0 · Reply
yamihere2
yamihere2 Dec. 24 at 5:54 PM
$CTXR Got scammed so bad here in 2021. Criminal, and it’s all legal?? Throw the old fk in jail
1 · Reply
Cholo_Swing_Trades
Cholo_Swing_Trades Dec. 24 at 5:43 PM
$CTXR wow hit .60s again after i sold this 2 years ago i made all my money back trading real stocks
0 · Reply
900fix
900fix Dec. 24 at 5:31 PM
$CTXR ML was slow walked. That was the start. It was all a scam by Lenny. He should be in jail with the board and that dim wit so called analyst Jason who kept pumping this.
0 · Reply
Justrise07
Justrise07 Dec. 24 at 4:51 PM
$MGRX 2pt $CTXR cover your loss
0 · Reply
Cooch23
Cooch23 Dec. 24 at 4:40 PM
$CTXR lmaoooo
0 · Reply
alexortega
alexortega Dec. 24 at 4:10 PM
$CTXR I think this company went bankrupt.
1 · Reply
Applebat
Applebat Dec. 24 at 3:45 PM
$CTXR Didn't I say $0.60 by the new year ? people laughed.
1 · Reply
mavox27460
mavox27460 Dec. 24 at 3:37 PM
$CTXR
0 · Reply
trader2360
trader2360 Dec. 24 at 3:32 PM
$CTXR selling stopped time for buying
0 · Reply
Justrise07
Justrise07 Dec. 24 at 3:31 PM
$CTXR why it’s down so much ?
1 · Reply
Oronero
Oronero Dec. 24 at 3:28 PM
$CTXR I recommend everyone buy this $CHR.X stock... A great company that just a few months ago had a market cap of hundreds and hundreds of millions of dollars. Excellent revenue and over $200 million in cash. 4.6 million shares in free float. Offerings pending and dilution completed. Do your part🗽🇺🇸 Bullish
0 · Reply
Stockprofiler
Stockprofiler Dec. 24 at 3:26 PM
$CTXR Hold for $1's
0 · Reply
Stockprofiler
Stockprofiler Dec. 24 at 3:24 PM
$CTXR Short Interest 2,398,448 shares - source: NASDAQ
0 · Reply
donein12
donein12 Dec. 24 at 3:24 PM
$CTXR Seems to me that any funds that held CTXR are dumping so not to have in holdings by Y/E. There release has not said anything we didn't know, nor did it mention if sales are going well since 12/1/2025. Nothing. So funds have finally given up.
0 · Reply
PrnceMichael
PrnceMichael Dec. 24 at 3:21 PM
$CTXR Now I’m giving you $CTXR … and the setup here might be EVEN BIGGER.** While everyone sleeps, Nasdaq: $CTXR just dropped a MAJOR press -
1 · Reply
Dogpoubd
Dogpoubd Dec. 24 at 3:20 PM
$CTXR bought 600$ at -26 . it then went down to -37! so i tripled my position . I won the money after all these years !
0 · Reply